MARKET

ACET

ACET

Adicet Bio Inc
NASDAQ
1.310
+0.030
+2.34%
Closed 18:39 07/17 EDT
OPEN
1.280
PREV CLOSE
1.280
HIGH
1.350
LOW
1.250
VOLUME
1.39M
TURNOVER
0
52 WEEK HIGH
3.770
52 WEEK LOW
1.050
MARKET CAP
107.65M
P/E (TTM)
-0.4437
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ACET last week (0708-0712)?
Weekly Report · 3d ago
Adicet stock jumps 10% on FDA fast track status for ADI-270
Adicet Bio, Inc. Stock jumps 10% on FDA fast track status for ADI-270 for renal cell carcinoma. The CAR-T cell therapy candidate is a type of kidney cancer. The company has received FDA designation for the treatment of the disease.
Seeking Alpha · 07/08 15:31
Adicet Bio Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Dow Jones · 07/08 14:10
HC Wainwright & Co. Reiterates Buy on Adicet Bio, Maintains $10 Price Target
Benzinga · 07/08 14:00
Buy Rating Affirmed for Adicet Bio on Strong Therapy Pipeline and Positive Financial Projections
TipRanks · 07/08 13:15
Adicet Bio’s ADI-270 Gets FDA Fast Track for Cancer Therapy
TipRanks · 07/08 11:27
Adicet Bio: FDA Grants Fast Track Designation To ADI-270 - Quick Facts
NASDAQ · 07/08 11:09
ADICET BIO RECEIVES FDA FAST TRACK DESIGNATION FOR ADI-270 IN METASTATIC/ADVANCED CLEAR CELL RENAL CELL CARCINOMA
Reuters · 07/08 11:00
More
About ACET
Adicet Bio, Inc. is a clinical stage biotechnology company. The Company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma (NHL). Its pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications. Its pipeline has several additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.

Webull offers Adicet Bio Inc stock information, including NASDAQ: ACET real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACET stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACET stock methods without spending real money on the virtual paper trading platform.